Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Core Insights - Gossamer Bio, Inc. is focused on developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1] Group 1 - Five scientific presentations related to seralutinib will be showcased at the European Respiratory Society (ERS) Congress 2025 [1]